B Cell Panel Variant 1
Scope. First design iteration (“Variant 1”) of an intracellular-capable B-cell phenotyping panel for the curator’s 3-laser (405/488/633), 14-detector conventional cytometer, leaning toward atypical / DN sub-populations and plasmablasts. This supersedes the surface-only DN2 Gating Strategy panel by adding T-bet (intracellular) — the marker that converts “DN2-phenotype” → confirmed DN2 / ABC — and unlocks the DN2:DN1 ratio centerpiece of Thesis Objectives and Grant Pitch via CXCR5. Presents one recommended single-tube workhorse (Panel 4) plus a three-tube suite (Panels 1–3) for when cell yield permits.
Research Question
Given a 3-laser/14-channel conventional instrument with intracellular-staining capability, what is the best B-cell panel — realistically a single tube — to confirm DN2/ABC identity, compute the DN2:DN1 ratio, and characterise the plasmablast/EF-effector output in acute dengue PBMCs?
Sources Used
- DN2 Gating Strategy — the surface-only 11-color predecessor; the resolution ceiling this variant breaks (no CXCR5/T-bet/FCRL5); CD11c-PE FMO + PE-Cy7→PE artifact precedent
- Thesis Objectives and Grant Pitch — DN2:DN1 ratio as centerpiece; “DN2-phenotype” claim cap; both-halves-of-the-thesis (DN2 + plasmablast) requirement
- Jenks2018 - DN2 B Cells and EF Pathway in SLE — formal DN2 = IgD⁻CD27⁻CXCR5⁻CD21⁻CD11c⁺T-bet⁺FCRL5⁺CD19ʰⁱ (the markers gated below); >90% CD21⁻CD11c⁺↔T-bet⁺ concordance in SLE
- Woodruff2020 - EF B Cell Responses in COVID-19 — DN1/DN2/DN3 resolution requires CXCR5; DN2:DN1 ratio as the cross-disease EF metric
- Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection — CD11c best single surface marker; T-bet/FCRL5 defining; surface gating undercounts
- Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue — the only dengue DN2-phenotype dataset; CD21⁻CD11c⁺ template; comparability target
- Sanz2025 - Human Atypical B Cells Overview — IgD-audit discipline (IgD retained below); “DN2-phenotype” terminology until T-bet confirms
Synthesis
Instrument & detector map
3 lasers (405/488/633), 14 fluorescence channels. No 561 (yellow-green) and no UV (355) → PE and all PE-tandems are forced onto the blue laser, making that line spillover-heavy. Six BV dyes share the violet line.
| Laser | Detector (BP) | Workhorse fluorochrome |
|---|---|---|
| Violet 405 | 450/40 | BV421 / Pacific Blue / eF450 |
| 510/50 | BV510 / Zombie Aqua / eF506 (fixable L/D) | |
| 610/20 | BV605 | |
| 660/20 | BV650 | |
| 710/50 | BV711 | |
| 780/60 | BV785 | |
| Blue 488 | 530/30 | FITC / BB515 / AF488 |
| 585/42 | PE | |
| 616/23 | PE-CF594 / PE-Dazzle594 | |
| 695/40 | PerCP-Cy5.5 / PerCP-eF710 | |
| 780/60 | PE-Cy7 | |
| Red 633 | 660/70 | APC / AF647 / eF660 |
| 730/45 | APC-R700 / AF700 | |
| 780/60 | APC-Cy7 / APC-Fire750 |
Two design constraints that drive every assignment
- 14 channels is the feasibility ceiling, not a target. Six BV on violet + five PE-family on blue make a maxed 14-color heavily compensation-bound; a clean 12–13 routinely beats a saturated 14. The recommended single tube (Panel 4) is deliberately 13-color.
- Only APC and BV421 are truly “premium” (bright and low spillover-spread into them); PE is a bright but crowded third. The four dim, defining atypical markers — CXCR5, CD11c, T-bet, FCRL5 — compete for those slots. Three premium channels, four markers → FCRL5 yields (it is corroborating; Jenks defines DN2 by T-bet⁺, and CD21⁻/CD11c⁺/CXCR5⁻ already bracket it). The three defining axes (CD11c⁺ / CXCR5⁻ / T-bet⁺) keep the premium channels in every panel.
Rules that apply to all panels (intracellular workflow)
- Fixable viability dye (eFluor506 / Zombie Aqua, violet 510/50) — mandatory once you fix/perm.
- All surface markers before fix; stain CXCR5/CXCR3 at 37 °C pre-fix (dim, fixation-sensitive).
- Intracellular markers (T-bet, Ki-67, IRF4) after a transcription-factor perm buffer (eBioscience FoxP3 / BD). Verify tandems survive that buffer (PE-Cy7, BV785, APC-Fire750, PerCP-Cy5.5) or move critical markers off them.
- Mandatory FMOs: CD11c-PE (every run — see PE-Cy7→PE artifact below), CXCR5, T-bet, any dim IC marker.
- Verify before ordering: these are fluorophore slots, not catalog SKUs. Confirm each conjugate/clone exists and run the final layout through a spillover-spreading matrix (BD Spectrum Viewer / Cytek Full Spectrum Viewer / FluoroFinder). Required step.
- DENV-antigen specificity is out of scope for all panels (no probes/tetramers) — that is the grant-level gap Thesis Objectives and Grant Pitch already tracks, not a pilot deliverable.
★ Recommended: Panel 4 — Single-Tube Workhorse (13-color)
Use this if you can realistically run one tube per patient (the budget/cell-yield reality for a fresh-PBMC pilot across ~19+ patients). Intracellular capability lets one tube do what previously needed a surface primary + an IC validation second tube. It confirms DN2/ABC, computes the DN2:DN1 ratio, and captures the plasmablast/EF-effector output — both halves of the thesis in one acquisition.
| Laser·BP | Fluorophore | Marker | Role |
|---|---|---|---|
| V·450/40 | BV421 | CXCR5 | ★ defining; 37 °C pre-fix |
| V·510/50 | eF506 (fixable) | Viability | — |
| V·610/20 | BV605 | CD20 | plasmablast = CD20⁻ |
| V·660/20 | BV650 | CD19 | lineage |
| V·710/50 | BV711 | Ki-67 (IC) | proliferation |
| V·780/60 | BV785 | IgD | DN gate |
| B·530/30 | FITC/BB515 | CD21 | DN subgate |
| B·585/42 | PE | CD11c | ★ defining; FMO mandatory |
| B·616/23 | PE-CF594 | CD71 | activation / EF effector |
| B·695/40 | PerCP-Cy5.5 | CD38 | plasmablast / activation |
| B·780/60 | PE-Cy7 | (empty) | left open by design — eliminates the PE-Cy7→PE false-CD11c artifact |
| R·660/70 | APC/eF660 | T-bet (IC) | ★ defining |
| R·730/45 | APC-R700 | CD27 | DN gate / plasmablast |
| R·780/60 | APC-Fire750 | Dump (CD3/CD14/CD16) | exclude |
Resolves in one tube: all 4 IgD×CD27 quadrants → true DN1 / DN2 / DN3 (CXCR5×CD21×CD11c) → T-bet⁺ confirmation; DN2:DN1 ratio (the centerpiece, impossible without CXCR5); plasmablasts (CD27ʰⁱCD38ʰⁱCD20⁻); EF-effector activation state (Ki-67 + CD71).
Design rationale for the empty PE-Cy7 slot: the dominant artifact on this instrument is PE-Cy7 tandem degradation bleeding into CD11c-PE (false DN2 positivity — flagged by the DN2 Gating Strategy council). Putting nothing abundant on PE-Cy7 removes the artifact at its source. If a 14th marker is wanted and the spreading matrix is clean, add IgM-PE-Cy7 (unswitched-vs-switched within DN) or CD24-PE-Cy7 (transitional) — but only after confirming minimal PE-Cy7→PE spread on your specific lot.
What it drops vs the full suite: isotype beyond IgD (IgM/IgG/IgA), CD24 transitional gating, FCRL5 corroboration, IRF4/CD138 ASC-commitment detail, CXCR3. If any of those is a per-patient must-have, run the suite below instead.
Full suite (Panels 1–3) — if cell yield / budget permits multiple tubes
Run Panel 1 on everyone as the suite anchor; add Panels 2–3 on a sex/age-balanced subset. Three 14-color tubes per fresh sample is cell- and cost-heavy — most pilots will not sustain it across the whole cohort.
Panel 1 — Confirmed DN2 / ABC + isotype (suite anchor, 14-color)
Panel 4 plus IgM (switch status) and CD24 (transitional), at the cost of CD71 and the empty-PE-Cy7 safeguard.
| Laser·BP | Fluorophore | Marker | Role |
|---|---|---|---|
| V·450/40 | BV421 | CXCR5 | ★; 37 °C pre-fix |
| V·510/50 | eF506 | Viability | — |
| V·610/20 | BV605 | CD20 | PB = CD20⁻ |
| V·660/20 | BV650 | CD19 | lineage |
| V·710/50 | BV711 | Ki-67 (IC) | proliferation |
| V·780/60 | BV785 | IgD | DN gate |
| B·530/30 | FITC/BB515 | CD21 | DN subgate |
| B·585/42 | PE | CD11c | ★; FMO mandatory |
| B·616/23 | PE-CF594 | IgM | switch status |
| B·695/40 | PerCP-Cy5.5 | CD38 | PB / transitional |
| B·780/60 | PE-Cy7 | CD24 | transitional; ⚠ tandem→PE risk (FMO CD11c) |
| R·660/70 | APC/eF660 | T-bet (IC) | ★ |
| R·730/45 | APC-R700 | CD27 | DN gate / PB |
| R·780/60 | APC-Fire750 | Dump | exclude |
Flex: swap Ki-67 ↔ FCRL5-BV711 for full Jenks confirmation over proliferation. Drop to 13: CD24 is the first cut (transitionals rare in adult dengue PBMC) — doing so also reopens the empty-PE-Cy7 safeguard.
Panel 2 — EF Effector & ASC Output (the plasmablast half, 14-color)
Trades CXCR5/isotype for the antibody-secreting differentiation axis — who is committing to plasmablast and proliferating.
| Laser·BP | Fluorophore | Marker | Role |
|---|---|---|---|
| V·450/40 | BV421 | IRF4 (IC) | ASC commitment (prefer IRF4 over BLIMP-1 — far better flow signal) |
| V·510/50 | eF506 | Viability | — |
| V·610/20 | BV605 | CD20 | PB = CD20⁻ |
| V·660/20 | BV650 | CD19 | lineage |
| V·710/50 | BV711 | Ki-67 (IC) | proliferation |
| V·780/60 | BV785 | CD138 | ASC maturation |
| B·530/30 | FITC/BB515 | CD21 | DN subgate |
| B·585/42 | PE | CD11c | ★; FMO |
| B·616/23 | PE-CF594 | CD71 | activation |
| B·695/40 | PerCP-Cy5.5 | CD38 | PB |
| B·780/60 | PE-Cy7 | IgD | DN gate |
| R·660/70 | APC/eF660 | T-bet (IC) | DN2 confirmation |
| R·730/45 | APC-R700 | CD27 | DN gate / PB |
| R·780/60 | APC-Fire750 | Dump | exclude |
Cost: no CXCR5 (DN1/DN3 not separated here) and isotype limited to IgD — acceptable because this tube’s job is the output, not DN subset anatomy.
Panel 3 — Isotype × Chemokine / DN-subset anatomy (subset of samples, 14-color)
Full class-switch distribution within each DN subset + the EF chemokine switch (CXCR5↓/CXCR3↑). Largely surface — the panel that least exploits the new IC capability, so the most optional.
| Laser·BP | Fluorophore | Marker | Role |
|---|---|---|---|
| V·450/40 | BV421 | CXCR5 | ★; 37 °C pre-fix |
| V·510/50 | eF506 | Viability | — |
| V·610/20 | BV605 | CD20 | PB |
| V·660/20 | BV650 | CD19 | lineage |
| V·710/50 | BV711 | IgG | switch |
| V·780/60 | BV785 | IgD | DN gate |
| B·530/30 | FITC/BB515 | CD21 | DN subgate |
| B·585/42 | PE | CD11c | ★; FMO |
| B·616/23 | PE-CF594 | IgM | switch |
| B·695/40 | PerCP-Cy5.5 | CD38 | PB |
| B·780/60 | PE-Cy7 | IgA | switch |
| R·660/70 | APC | CXCR3 | EF migration; 37 °C pre-fix |
| R·730/45 | APC-R700 | CD27 | DN gate / PB |
| R·780/60 | APC-Fire750 | Dump | exclude |
Also surfaces the CXCR5⁺ DN subsets (DN1/DN4) that a standard CXCR5⁻ EF gate discards (current watch item). Option: swap IgA→T-bet-APC (move CXCR3→BV711) to add IC confirmation here.
How the four panels relate
| Panel 4 (rec.) | Panel 1 | Panel 2 | Panel 3 | |
|---|---|---|---|---|
| Colors | 13 | 14 | 14 | 14 |
| Tubes | 1 (all patients) | suite anchor | + subset | + subset |
| DN2 confirmation (T-bet) | ✅ | ✅ | ✅ | ✗ (optional) |
| DN2:DN1 ratio (CXCR5) | ✅ | ✅ | ✗ | ✅ |
| Plasmablast ID (CD20⁻CD38ʰⁱCD27ʰⁱ) | ✅ | ✅ | ✅ | ✅ |
| ASC commitment (CD138/IRF4) | ✗ | ✗ | ✅ | ✗ |
| Proliferation/activation (Ki-67/CD71) | ✅/✅ | ✅/✗ | ✅/✅ | ✗ |
| Isotype | IgD only | +IgM | IgD only | IgD/M/G/A |
| Transitional (CD24) | ✗ | ✅ | ✗ | ✗ |
| Chemokine switch (CXCR3) | ✗ | ✗ | ✗ | ✅ |
Bottom line: build and validate Panel 4 first — it closes the headline deficiency (DN2 confirmation), unlocks the DN2:DN1 ratio, and captures plasmablasts in a single clean 13-color tube. Treat Panels 1–3 as the multi-tube suite for when cells and budget allow, with Panel 1 as the anchor.
Open Questions
- Cells per fresh draw / per-tube cost? This is the single fact that decides Panel-4-only vs the suite. If multi-tube is feasible on a subset, prioritise Panel 2 (ASC output) over Panel 3.
- Does the SLE CD21⁻/CXCR5⁻ ↔ T-bet⁺ concordance (Jenks2018, >90%) hold in acute dengue? Panel 4 now lets you measure it directly — the first dengue test of whether “DN2-phenotype” = true DN2.
- Will the chosen PE-Cy7 conjugate (if the 14th slot is used) pass the spreading-matrix check for CD11c-PE, or should PE-Cy7 stay empty?
- Do T-bet-APC/eF660 and Ki-67-BV711 survive the curator’s specific TF perm buffer without epitope/tandem loss? (Validate before cohort runs.)
- Should this feed the queued Research Plan Rev 5 as the new primary panel (replacing the surface-only 11-color)?
Related Pages
DN2 Gating Strategy, Thesis Objectives and Grant Pitch, Research Plan - DN B Cell Expansion in Dengue, DN2 B Cell, DN3 B Cell, Double-Negative B Cell, Atypical B Cell, Age-Associated B Cell, Plasmablast, Activated Naive B Cell, Conventional Flow Cytometry, Spectral Flow Cytometry, CXCR5, CXCR3, CD11c, CD21, T-bet, FCRL5, CD71, IRF4, CD138, CD24, IgD, IgM, IgG, CD27, CD38, CD19, CD20, Jenks2018 - DN2 B Cells and EF Pathway in SLE, Woodruff2020 - EF B Cell Responses in COVID-19, Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, Sanz2025 - Human Atypical B Cells Overview